Alkalinization
Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Vitamin D  COVID-19 treatment studies for Vitamin D  C19 studies: Vitamin D  Vitamin D   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Hospitalization 93% Improvement Relative Risk c19early.org/d Allami et al. Vitamin D for COVID-19 Sufficiency Are vitamin D levels associated with COVID-19 outcomes? Retrospective 171 patients in Iraq Lower hospitalization with higher vitamin D levels (p<0.000001) Allami et al., 1st Samarra Int. Conference for P.., doi:10.1063/5.0121166 Favors vitamin D Favors control
The risk of up normal values of two parameters obesity and vitamin D in incidence of coronavirus disease-19 among Iraqi patients
Allami et al., 1st Samarra International Conference for Pure and Applied Sciences (SICPS2021), doi:10.1063/5.0121166
Allami et al., The risk of up normal values of two parameters obesity and vitamin D in incidence of coronavirus disease-19.., 1st Samarra International Conference for Pure and Applied Sciences (SICPS2021), doi:10.1063/5.0121166
Nov 2022   Source   PDF  
  Twitter
  Facebook
Share
  All Studies   Meta
Retrospective 86 COVID-19 hospitalized patients and 86 healthy controls in Iraq, showing COVID-19 cases associated with severe vitamin D deficiency.
This is the 146th of 175 COVID-19 sufficiency studies for vitamin D, which collectively show higher levels reduce risk with p<0.0000000001 (1 in 18 vigintillion).
risk of hospitalization, 92.5% lower, OR 0.07, p < 0.001, high D levels (≥10ng/mL) 91, low D levels (<10ng/mL) 80, adjusted per study, inverted to make OR<1 favor high D levels (≥10ng/mL), case control OR, multivariable.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Allami et al., 8 Nov 2022, retrospective, Iraq, peer-reviewed, 6 authors.
Contact: ahmed.suleiman@uoanbar.edu.iq.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperVitamin DAll
The Risk of Up Normal Values of Two Parameters Obesity and Vitamin D in Incidence of Coronavirus Disease-19 Among Iraqi Patients
Risala H Allami, Ahmed A Suleiman, Raghad S Mouhamad, Maha H Abdullah, Mustafa Y Alsudani, Ali H Adhiah
The new epidemic of coronavirus disease-19 outbreak has caused rapid morbidity and mortality rates worldwide, and health parameters have been proposed to influence disease progression. Among these parameters are index of body mass (BMI) and D vitamin. 86 patients with same number of control were studied( case-control) to find the relationship between the BMI, vitamin D and risk of COVID-19. Vitamin D (25-hydroxyvitamin D) serum level was estimated by ELISA. Results revealed that the age mean value was elevated significantly in cases compared to normal persons , and 50% of patients were 50 years of age or older. patients BMI were higher significantly in comparison with controls, and most of patients were overweight/obese (76.7%). The Vitamin D level decreased in patients significantly compared to control, and most of patients were severely-deficient (75.6%). Logistic-regression-analysis depicted a high risk of COVID-19 in obese cases (OR= 26.39; 95% interval of confidence [CI]: 7.02-99.24; p < 0.001), and in patients with severe deficient in vitamin D (OR = 13.34; 95% CI: 6.32-28.19; < 0.001). Moreover, overweight/obese patients severely deficient in vitamin D were at high risk of developing COVID-19 infection (OR = 230.55; 95% CI: 43.98-1208.67; p < 0.001). Curve analysis of ROC(Receiver-operating-characteristic) showed that BMI and vitamin D occupied under curve significant area (0.770 and 0.864, respectively). In conclusions, the study indicated that individuals who were overweight/obese and severely deficient in vitamin D were more susceptible to develop COVID-19.
References
Ali, None, J. Infect. Public Health, doi:10.1016/j.jiph.2020.06.021
Amiri, Behnezhad, Hasani, None, Obes. Med, doi:10.1016/j.obmed.2020.100196
Annweiler, Cao, Sabatier, None, Maturitas, doi:10.1016/j.maturitas.2020.06.003
De Heredia, Gómez-Martínez, Marcos, None, CUP
Ge, Wang, Yuan, Xiao, Wang et al., None, Eur. J. Clin. Microbiol. Infect. Dis, doi:10.1007/s10096-020-03874-z
Gombart, None, Future Microbiol
Hegde, Dhurandhar, None, Clin. Microbiol. Infect
Holick, None, Rev. Endocr. Metab. Disord, doi:10.1007/s11154-017-9424-1
Hussain, Mahawar, Xia, Yang, El-Hasani, None, Obes. Res. Clin. Pract, doi:10.1016/j.orcp.2020.07.002
Kennel, Drake, Hurley, None, Mayo Clin. Proc
Kościuczuk, Lisowski, Jarczak, Strzałkowska, Jóźwik et al., None, Mol. Biol. Rep
Lee, None, Best Pract. Res. Clin. Endocrinol. Metab, doi:10.1016/j.beem.2011.03.001
Lisowski, Jarczak, Strzałkowska, Jóźwik, Horbańczuk et al., None, Mol. Biol. Rep
Liu, Zhang, Li, Li, Zhou et al., None, J. Clin. Virol
Maresova, Javanmardi, Barakovic, Barakovic, Husic et al., None, BMC Public Health, doi:10.1186/s12889-019-7762-5
Montecino-Rodriguez, Berent-Maoz, Dorshkind, None, J. Clin. Invest
Muscogiuri, Pugliese, Barrea, Savastano, Colao, None, Metabolism, doi:10.1016/j.metabol.2020.154251
Nuttall, None, Nutr. Today, doi:10.1097/NT.0000000000000092
O'shea, Corrigan, Dunne, Jackson, Woods et al., None, Int. J. Obes, doi:10.1038/ijo.2013.16
Palacios, Gonzalez, None, J. Steroid Biochem. Mol. Biol, doi:10.1016/j.jsbmb.2013.11.003
Pan, Liu, Wang, Guo, Hao et al., None, JAMA -J. Am. Med. Assoc, doi:10.1001/jama.2020.6130
Peng, None, Biomed. Pharmacother, doi:10.1016/j.biopha.2020.110499
Prietl, Treiber, Pieber, Amrein, None, Nutrients, doi:10.3390/nu5072502
Quesada-Gomez, Castillo, Bouillon, None, J. Steroid Biochem. Mol. Biol, doi:10.1016/j.jsbmb.2020.105719
Rojas-Osornio, Cruz-Hernández, Drago-Serrano, Campos-Rodríguez, None, Obes. Res. Clin. Pract, doi:10.1016/j.orcp.2019.05.003
Tamara, Tahapary, None, Diabetes Metab. Syndr. Clin. Res. Rev, doi:10.1016/j.dsx.2020.05.020
Wilder-Smith, Chiew, Lee, None, Lancet Infect. Dis, doi:10.1016/S1473-3099(20)30129-8
Yang, Liu, Zhang, Li, Li et al., None, J. Clin. Virol, doi:10.1016/j.jcv.2020.104475
Yegorov, Bromage, Boldbaatar, Ganmaa, None, Front. Nutr, doi:10.3389/fnut.2019.00166
Loading..
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit